Interventional Cardiology & Vascular Therapies was Boston Scientific’s largest product and service line in fiscal 2025, bringing in $4.64B of $20.07B (23%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | — | $3.79B | $4.20B | $4.64B | ||||||
| Global Interventional Cardiology (Ic) Reporting Unit | — | — | — | — | ||||||
| Interventional Cardiology Therapies | $2.23B | — | — | — | ||||||
| Cardiac Rhythm Management | $2.10B | $2.22B | $2.28B | $2.33B | ||||||
| Endoscopy | — | $2.48B | $2.69B | $2.92B | ||||||
| Global Endoscopy (Endo) Reporting Unit | $2.22B | — | — | — | ||||||
| Global Crm Reporting Unit | — | — | — | — | ||||||
| Urology | — | $1.96B | $2.20B | $2.71B | ||||||
| Global Urology & Pelvic Health Reporting Unit | $1.77B | — | — | — | ||||||
| Global Peripheral Interventions (Pi) Reporting Unit | $1.90B | — | — | — | ||||||
| Electrophysiology | — | $800.00M | $1.90B | $3.33B | ||||||
| Electrophysiology (Ep) | $585.00M | — | — | — | ||||||
| Watchman | $1.02B | $1.27B | $1.52B | $1.96B | ||||||
| Neuromodulation | — | $976.00M | $1.11B | $1.20B | ||||||
| Global Neuromodulation (Nm) Reporting Unit | $917.00M | — | — | — | ||||||
| Interventional Oncology & Embolization | — | $736.00M | $856.00M | $996.00M | ||||||
| Global Electrophysiology (Ep) Reporting Unit | — | — | — | — | ||||||
| Specialty Pharmaceuticals | — | — | — | — | ||||||
| Other | -$60.00M | — | — | — | ||||||
| Total | $12.68B | $14.24B | $16.75B | $20.07B |
Boston Scientific brought in $20.07B from its eight product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 19.9% from $16.75B in fiscal 2024. Interventional Cardiology & Vascular Therapies was the largest at $4.64B (23.1%), ahead of Electrophysiology at $3.33B (16.6%) and Endoscopy at $2.92B (14.5%). The other five lines brought in $9.19B combined.
Compared with fiscal 2024, Electrophysiology grew fastest, up 74.6% to $3.33B. Every line above 2% of revenue grew.
Boston Scientific began breaking out Interventional Cardiology & Vascular Therapies in fiscal 2023, Endoscopy in fiscal 2023, Urology in fiscal 2023 and Electrophysiology in fiscal 2023. Boston Scientific stopped reporting Interventional Cardiology Therapies ($2.23B in fiscal 2022), Global Endoscopy (Endo) Reporting Unit ($2.22B in fiscal 2022), Global Peripheral Interventions (Pi) Reporting Unit ($1.90B in fiscal 2022) and three others as separate lines.
U.S was Boston Scientific’s largest region in fiscal 2025, bringing in $12.86B of $20.07B (64%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Country_Us Excluding Other Net Sales | $7.63B | — | — | — | ||||||
| U.S | — | $8.43B | $10.21B | $12.86B | ||||||
| United States | — | — | — | — | ||||||
| Int'L | — | — | — | $7.21B | ||||||
| Non-Us | — | — | — | — | ||||||
| Europe, Middle East & Africa | — | $2.86B | $3.23B | — | ||||||
| Emea | $2.53B | — | — | — | ||||||
| Asia-Pacific | — | $2.40B | $2.69B | — | ||||||
| Apac | $2.12B | — | — | — | ||||||
| Asia Pacific | — | — | — | — | ||||||
| Latin America & Canada | $469.00M | $560.00M | $624.00M | — | ||||||
| Total | $12.74B | $14.24B | $16.75B | $20.07B |
Boston Scientific brought in $20.07B from its two regions in fiscal 2025, the year ended December 31, 2025. Boston Scientific regrouped these regions after fiscal 2024, so the total does not compare directly with that year's $16.75B. U.S was the largest at $12.86B (64.1%), ahead of Int'L at $7.21B (35.9%).
Boston Scientific began breaking out Int'L in fiscal 2025, when it brought in $7.21B. Boston Scientific stopped reporting Country_Us Excluding Other Net Sales ($7.63B in fiscal 2022), Europe, Middle East & Africa ($3.23B in fiscal 2024), Asia-Pacific ($2.69B in fiscal 2024) and three others as separate regions.
Cardiovascular was Boston Scientific’s largest segment in fiscal 2025, bringing in $13.25B of $20.07B (66%).
| Segment | FY 2008 | FY 2009 | FY 2010 | FY 2017 | FY 2018 | FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardiovascular | $7.83B | $8.82B | $10.76B | $13.25B | |||||||
| Medsurg | $4.91B | $5.42B | $5.99B | $6.82B | |||||||
| Rhythm & Neuro | — | — | — | — | |||||||
| Cardiac Rhythm Management | — | — | — | — | |||||||
| Endoscopy | — | — | — | — | |||||||
| Urology Women's/Health | — | — | — | — | |||||||
| Neurovascular | — | — | — | — | |||||||
| Neuromodulation | — | — | — | — | |||||||
| Electrophysiology | — | — | — | — | |||||||
| Total | $12.74B | $14.24B | $16.75B | $20.07B |
Boston Scientific brought in $20.07B from its two segments in fiscal 2025, the year ended December 31, 2025. That was up 19.9% from $16.75B in fiscal 2024. Cardiovascular was the largest at $13.25B (66.0%), ahead of Medsurg at $6.82B (34.0%).
Compared with fiscal 2024, Cardiovascular grew 23.2% to $13.25B and Medsurg grew 13.9% to $6.82B. From fiscal 2022 to 2025, combined revenue from these segments grew from $12.74B to $20.07B, a compound annual growth rate of 16.4%. Cardiovascular's share of the total rose from 61.5% to 66.0%.
Boston Scientific (BSX) reports its revenue by product and service, by geography and by segment. In fiscal 2025, Interventional Cardiology & Vascular Therapies was its largest product and service line, bringing in $4.64B (23.1% of the total), followed by Electrophysiology at $3.33B (16.6%).
Interventional Cardiology & Vascular Therapies was Boston Scientific's largest product and service line in fiscal 2025, bringing in $4.64B, or 23.1% of the $20.07B total across its eight product and service lines.
U.S was Boston Scientific's largest region in fiscal 2025, bringing in $12.86B, or 64.1% of the $20.07B total across its two regions.
Cardiovascular was Boston Scientific's largest segment in fiscal 2025, bringing in $13.25B, or 66.0% of the $20.07B total across its two segments.
Among Boston Scientific's product and service lines that make up at least 2% of revenue, Electrophysiology grew fastest in fiscal 2025, up 74.6% from $1.90B to $3.33B.
Every figure comes from Boston Scientific's annual financial filings, as reported. Each line keeps the name Boston Scientific gives it, and years follow its fiscal calendar.
Boston Scientific's revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.